In a filing, Vertex Pharmaceuticals, Inc revealed its EVP and Chief Legal Officer Biller Jonathan unloaded Company’s shares for reported $0.28 million on Oct 02 ’25. In the deal valued at $404.21 per share,694 shares were sold. As a result of this transaction, Biller Jonathan now holds 15,653 shares worth roughly $6.38 million.
Then, Biller Jonathan bought 694 shares, generating $280,522 in total proceeds.
Before that, Bhatia Sangeeta N. sold 266 shares. Vertex Pharmaceuticals, Inc shares valued at $102,860 were divested by the Director at a price of $386.69 per share. As a result of the transaction, Bhatia Sangeeta N. now holds 4,565 shares, worth roughly $1.86 million.
Leerink Partners upgraded its Vertex Pharmaceuticals, Inc [VRTX] rating to an Outperform from a a Market perform in a research note published recently. A number of analysts have revised their coverage, including Raymond James’s analysts, who began to cover the stock in early September with a ‘”a Mkt perform”‘ rating. Wells Fargo also remained covering VRTX and has increased its forecast on August 06, 2025 with a “an Overweight” recommendation from previously “an Equal weight” rating. Wolfe Research revised its rating on May 07, 2025. It rated VRTX as “a Peer perform” which previously was an “an Outperform”.
Price Performance Review of VRTX
On Friday, Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] saw its stock fall -1.70% to $407.79. Over the last five days, the stock has gained 1.11%. Vertex Pharmaceuticals, Inc shares have fallen nearly -11.15% since the year began. Nevertheless, the stocks have risen 1.26% over the past one year.
How much short interest is there in Vertex Pharmaceuticals, Inc?
A steep rise in short interest was recorded in Vertex Pharmaceuticals, Inc stocks on 2025-09-30, dropping by 82234.0 shares to a total of 3.56 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 3.64 million shares. There was a decline of -2.31%, which implies that there is a negative sentiment for the stock.